cancidas and Mucormycosis

cancidas has been researched along with Mucormycosis* in 2 studies

Other Studies

2 other study(ies) available for cancidas and Mucormycosis

Article	Year
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 We have determined the in vitro activities of amphotericin B (AMB), voriconazole, posaconazole (PSC), itraconazole (ITC), ravuconazole, terbinafine, and caspofungin against five strains of Cunninghamella bertholletiae and four of Cunninghamella echinulata. The best activity was shown by terbinafine against both species (MIC range = 0.3 to 0.6 μg/ml) and PSC against Cunninghamella bertholletiae (MIC = 0.5 μg/ml). We have also evaluated the efficacies of PSC, ITC, and AMB in neutropenic and diabetic murine models of disseminated infection by Cunninghamella bertholletiae. PSC at 40, 60, or 80 mg/kg of body weight/day was as effective as AMB at 0.8 mg/kg/day in prolonging survival and reducing the fungal tissue burden in neutropenic mice. PSC at 80 mg/kg/day was more effective than AMB at 0.8 mg/kg/day in reducing the fungal load in brain and lung of diabetic mice. Histological studies revealed an absence of fungal elements in organs of mice treated with either AMB at 0.8 mg/kg/day or PSC at 60 or 80 mg/kg/day in both models. ITC showed limited efficacy in both models. PSC could be a therapeutic option for the treatment of systemic infections caused by Cunninghamella bertholletiae. Topics: Amphotericin B; Animals; Antifungal Agents; Caspofungin; Cunninghamella; Diabetes Mellitus, Experimental; Echinocandins; Itraconazole; Lipopeptides; Male; Mice; Microbial Sensitivity Tests; Mucormycosis; Pyrimidines; Thiazoles; Triazoles; Voriconazole	2010
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7 We evaluated the in vitro susceptibilities of 217 zygomycetes to amphotericin B, ketoconazole, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, and flucytosine. The significant in vitro activity of posaconazole against several species appears to support its reported clinical efficacy. Decreased susceptibility to amphotericin B was noted with Cunninghamella bertholletiae. Topics: Amphotericin B; Antifungal Agents; Caspofungin; Echinocandins; Fluconazole; Flucytosine; Humans; In Vitro Techniques; Itraconazole; Ketoconazole; Lipopeptides; Microbial Sensitivity Tests; Mucormycosis; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole	2007

Article

Year

In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.

Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11

We have determined the in vitro activities of amphotericin B (AMB), voriconazole, posaconazole (PSC), itraconazole (ITC), ravuconazole, terbinafine, and caspofungin against five strains of Cunninghamella bertholletiae and four of Cunninghamella echinulata. The best activity was shown by terbinafine against both species (MIC range = 0.3 to 0.6 μg/ml) and PSC against Cunninghamella bertholletiae (MIC = 0.5 μg/ml). We have also evaluated the efficacies of PSC, ITC, and AMB in neutropenic and diabetic murine models of disseminated infection by Cunninghamella bertholletiae. PSC at 40, 60, or 80 mg/kg of body weight/day was as effective as AMB at 0.8 mg/kg/day in prolonging survival and reducing the fungal tissue burden in neutropenic mice. PSC at 80 mg/kg/day was more effective than AMB at 0.8 mg/kg/day in reducing the fungal load in brain and lung of diabetic mice. Histological studies revealed an absence of fungal elements in organs of mice treated with either AMB at 0.8 mg/kg/day or PSC at 60 or 80 mg/kg/day in both models. ITC showed limited efficacy in both models. PSC could be a therapeutic option for the treatment of systemic infections caused by Cunninghamella bertholletiae.

Topics: Amphotericin B; Animals; Antifungal Agents; Caspofungin; Cunninghamella; Diabetes Mellitus, Experimental; Echinocandins; Itraconazole; Lipopeptides; Male; Mice; Microbial Sensitivity Tests; Mucormycosis; Pyrimidines; Thiazoles; Triazoles; Voriconazole

2010

In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.

Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7

We evaluated the in vitro susceptibilities of 217 zygomycetes to amphotericin B, ketoconazole, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, and flucytosine. The significant in vitro activity of posaconazole against several species appears to support its reported clinical efficacy. Decreased susceptibility to amphotericin B was noted with Cunninghamella bertholletiae.

Topics: Amphotericin B; Antifungal Agents; Caspofungin; Echinocandins; Fluconazole; Flucytosine; Humans; In Vitro Techniques; Itraconazole; Ketoconazole; Lipopeptides; Microbial Sensitivity Tests; Mucormycosis; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole

2007